Bfl-1 Antibody
| Code | Size | Price |
|---|
| PSI-3873-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3873-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Bfl-1 Antibody: GRS, BFL1, ACC-1, ACC-2, HBPA1, BCL2L5, GRS, Bcl-2-related protein A1, Bcl-2-like protein 5, Bcl2-L-5
Application Note:
Bfl-1 antibody can be used for the detection of Bfl-1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
Bfl-1 Antibody: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells and is caused by caspase activation. Proteins that comprise the Bcl-2 family appear to control the activation of these enzymes. One such member is multi-domain antiapoptotic protein Bfl-1, which is overexpressed in stomach and other cancers. Bfl-1 can interact with Bax and suppress apoptosis by inhibiting the release of cytochrome c and caspase-3 activation. It is upregulated in cisplatin-resistant human bladder tumors, suggesting that its expression may be important for cisplatin resistance and inhibition of apoptosis in cancer cells.
Background References:
- Lockshin RA, Osborne B, and Zakeri Z. Cell death in the third millennium. Cell Death Differ. 2000; 7:2-7.
- Choi SS, Park IC, Yun JW, et al. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11:1693-8.
- Kim JK, Kim KD, Lee E, et al. Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett. 2004; 212:61-70.
- Zhang H, Cowan-Jacob SW, Simonen M, et al. Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells. J. Biol. Chem. 2000; 275:11092-9.
Buffer:
Bfl-1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (92%)
Immunogen:
Bfl-1 antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human Bfl-1.
The immunogen is located within the last 50 amino acids of Bfl-1.
The immunogen is located within the last 50 amino acids of Bfl-1.
NCBI Gene ID #:
597
NCBI Official Name:
BCL2-related protein A1
NCBI Official Symbol:
BCL2A1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 19 kDa
Observed: 20 kDa
Observed: 20 kDa
Protein Accession #:
NP_004040
Protein GI Number:
4757840
Purification:
Bfl-1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
At least two isoforms of Bfl-1 are known to exist; this antibody will only detect the larger isoform.
Swissprot #:
Q16548
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Bfl-1 Peptide | PSI-3873P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|